Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm |
Domain |
PF13516 Leucine Rich repeat PF02758 PAAD/DAPIN/Pyrin domain |
Function |
Suppresses TNF- and CD40-induced NFKB1 activity at the level of the IKK complex, by inhibiting NFKBIA degradation induced by TNF. When associated with PYCARD, activates CASP1, leading to the secretion of mature proinflammatory cytokine IL1B. May be a component of the inflammasome, a protein complex which also includes PYCARD, CARD8 and CASP1 and whose function would be the activation of proinflammatory caspases. |
Biological Process |
GO:0001819 positive regulation of cytokine production GO:0009306 protein secretion GO:0010950 positive regulation of endopeptidase activity GO:0010952 positive regulation of peptidase activity GO:0032611 interleukin-1 beta production GO:0032612 interleukin-1 production GO:0032651 regulation of interleukin-1 beta production GO:0032652 regulation of interleukin-1 production GO:0032731 positive regulation of interleukin-1 beta production GO:0032732 positive regulation of interleukin-1 production GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0045862 positive regulation of proteolysis GO:0050663 cytokine secretion GO:0050701 interleukin-1 secretion GO:0050702 interleukin-1 beta secretion GO:0050704 regulation of interleukin-1 secretion GO:0050706 regulation of interleukin-1 beta secretion GO:0050707 regulation of cytokine secretion GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050715 positive regulation of cytokine secretion GO:0050716 positive regulation of interleukin-1 secretion GO:0050718 positive regulation of interleukin-1 beta secretion GO:0051047 positive regulation of secretion GO:0051222 positive regulation of protein transport GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:1903532 positive regulation of secretion by cell GO:1904951 positive regulation of establishment of protein localization GO:2000116 regulation of cysteine-type endopeptidase activity GO:2001056 positive regulation of cysteine-type endopeptidase activity |
Molecular Function |
GO:0032090 Pyrin domain binding |
Cellular Component |
GO:0000781 chromosome, telomeric region GO:0000784 nuclear chromosome, telomeric region GO:0044454 nuclear chromosome part GO:0098687 chromosomal region |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between NLRP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of NLRP2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of NLRP2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of NLRP2 in various data sets.
|
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRP2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of NLRP2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between NLRP2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | NLRP2 |
Name | NLR family, pyrin domain containing 2 |
Aliases | FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ...... |
Chromosomal Location | 19q13.42 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting NLRP2 collected from DrugBank database. |
There is no record. |